Home » Stocks » Allogene Therapeutics

Allogene Therapeutics, Inc. (ALLO)

Stock Price: $36.34 USD -2.89 (-7.37%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $36.00 -0.34 (-0.94%) Oct 19, 7:52 PM

Stock Price Chart

Key Info

Market Cap 5.06B
Revenue (ttm) n/a
Net Income (ttm) -227.22M
Shares Out 139.29M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $36.34
Previous Close $39.23
Change ($) -2.89
Change (%) -7.37%
Day's Open 39.29
Day's Range 36.29 - 39.55
Day's Volume 502,211
52-Week Range 17.43 - 55.00

More Stats

Market Cap 5.06B
Enterprise Value 4.16B
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 139.29M
Float 67.31M
EPS (basic) -2.12
EPS (diluted) -2.11
FCF / Share -1.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.36M
Short Ratio 16.37
Short % of Float 15.39%
Beta 1.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.16
Revenue n/a
Operating Income -240.43M
Net Income -227.22M
Free Cash Flow -210.55M
Net Cash 903.95M
Net Cash / Share 6.49
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.08%
ROE -24.98%
ROIC -37.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 11
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$53.50*
(47.22% upside)
Low
37.0
Current: $36.34
High
70.0
Target: 53.50
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-202-193
Net Income-185-212
Shares Outstanding10128.95
Earnings Per Share-1.83-7.31
Operating Cash Flow-137-44.65
Capital Expenditures-50.79-3.23
Free Cash Flow-188-47.89
Cash & Equivalents535461
Net Cash / Debt535461
Assets718774
Liabilities88.7870.69
Book Value629703
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Allogene Therapeutics, Inc.
Country United States
Employees 236
CEO David D. Chang

Stock Information

Ticker Symbol ALLO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALLO
IPO Date October 11, 2018

Description

Allogene Therapeutics, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.